News
PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...
PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...
The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.
More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...
A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.
PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.
Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).
(Alliance News) - Partners Group Private Equity Ltd on Tuesday said its investment manager, Partners Group Holding AG, has agreed to exit its existing stake in PCI Pharma Services and reinvest as a ...
Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corpo ...
Hosted on MSN5mon
Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn - MSNUS private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn).
Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results